Printer Friendly

INAMED CORP. ANNOUNCES RESULTS

 INAMED CORP. ANNOUNCES RESULTS
 SANTA BARBARA, Calif., March 31 /PRNewswire/ -- INAMED Corp.


(NASDAQ: IMDC), headquartered here, today reported a net loss of $2,810,746, or $.35 per share, on sales of $42,283,931 for the year ended Dec. 31, 1991, as compared to a net loss of $66,814, or $.01 per share, on sales of $35,741,557 in the prior year.
 The company said its 1991 financial results were affected adversely by the write-off of approximately $4.43 million of certain inventories and intangible assets related to the silicone gel-filled implants covered by the recent FDA regulatory activity. It also made an adjustment to increase accrued self-insurance reserves by approximately $1 million. The reported loss has resulted in an income tax benefit of $845,000 to be carried forward.
 In February 1992, an FDA panel recommended that the use of silicone gel-filled breast implants be limited to reconstruction surgery and limited augmentation cases where the recipient agrees to be included in on-going studies. The FDA is expected to decide on the panel's recommendation in April 1992.
 "On the positive side," said Donald K. McGhan, INAMED president and chief executive officer, "the company experienced continued sales growth in 1991 despite the gel-filled implant controversy and the economic recession. We are experiencing strong benefit from reduced competition domestically and internationally as well as an expansion of our market share in these areas. We anticipate accelerated sales growth and profitability in 1992."
 McGhan noted that sales of saline-filled breast implants have increased "substantially" since the FDA called for a voluntary moratorium on the sale of silicone gel-filled implants in January 1992. "Management is committed to servicing the medical industry and the public at large with safe and reliable products that enhance the quality of life of the patients. Further, we will continue to develop our own implant products and silicone components for other medical device companies."
 INAMED Corp. is a medical device company with 13 operating subsidiaries in the United States and Europe. The company develops, manufactures and markets medical devices for the plastic and reconstructive, bariatric and general surgery markets.
 INAMED CORP. FINANCIAL SUMMARY
 Fiscal year ended Dec. 31,
 1991 1990
 Sales $42,283,931 $35,741,557
 Net income (2,810,746) (66,814)
 Profit per share ($0.35) ($0.01)
 Weighted average number of
 share outstanding 8,099,483 7,963,081
 -0- 3/31/92
 /CONTACT: Donald K. McGhan, chairman of INAMED, 805-684-6277; or Jimmy Caplan of Market Makers, 805-569-6919, for INAMED/
 (IMDC) CO: INAMED Corp. ST: California IN: MTC SU: ERN


JL-EH -- LA012 -- 3255 03/31/92 09:15 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 31, 1992
Words:436
Previous Article:LOWE'S ANNOUNCES MARCH SALES UP 20 PERCENT DECLARES CASH DIVIDEND
Next Article:DUKE POWER TO ANNOUNCE FILLING OF KEY TOP MANAGEMENT POSITION
Topics:


Related Articles
INAMED CORP. VOLUNTARILY SUSPENDS SHIPMENTS OF GEL-FILLED BREAST IMPLANTS
INAMED CORP. VOLUNTARILY SUSPENDS SHIPMENTS OF GEL-FILLED BREAST IMPLANTS
INAMED SUBSIDIARY FILES SUIT AGAINST FDA, COMMISSIONER KESSLER; COMPANY CALLS AGENCY'S BREAST IMPLANT REVIEW SCIENTIFICALLY, LEGALLY FLAWED
INAMED SUBSIDIARY HALTS SUIT FILED AGAINST FDA AND COMMISSIONER KESSLER
INAMED CORP. REPORTS RESULTS
INAMED CORP. APPOINTS GERALD L. EHRENS CHIEF OPERATING OFFICER AND VICE PRESIDENT OF CORPORATE DEVELOPMENT
INAMED REPORTS RECORD SECOND QUARTER AND SIX-MONTH SALES AND PROFITS
INAMED SCHEDULES ADJOURNED ANNUAL MEETING
TWO INAMED OFFICERS PURCHASE 400,000 SHARES OF COMPANY STOCK

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters